drugset / Trial / NCT04646889

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

NCT04646889

Phase 1 Completed 46 enrolled Arthrosi Therapeutics IQVIA Pty Ltd · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.

Timeline

Start
2021-01-14
Primary completion
2022-06-27
Completion
2022-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject AR882 Unknown